Health Care • Other Pharmaceuticals
$980.88 ▲ +20.32
(+2.12%)
MKT CAP: $114.36B • VOL: 721.5K
52W L $724 52W H $1,030
MCK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $403.43B | $359.05B | $308.95B |
| YoY Revenue Growth % | +12.4% | +16.2% | — |
| Gross Profit | $14.55B | $13.32B | $135.94B |
| Gross Margin % | 3.6% | 3.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $6.21B | $4.42B | $3.91B |
| Operating Margin % | 1.5% | 1.2% | 1.3% |
| Net Income (GAAP) | $4.76B | $3.29B | $3.00B |
| EBITDA (Normalized) | $6.56B | $4.85B | $15.03B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $6.16B | $6.08B | $4.31B |
| Capital Expenditures (CapEx) | $436.0M | $537.0M | $13.90B |
| Free Cash Flow (FCF) | $5.72B | $5.55B | -$9.59B |
| FCF Margin % | 1.4% | 1.5% | -3.1% |
| Return on Invested Capital (ROIC %) | 31.8% | 28.1% | 1.4% |
| Cash & Short-Term Equivalents | $2.96B | $1.13B | $40.78B |
| Total Debt (Short + Long Term) | $19.70B | $16.63B | $86.75B |
| Total Stockholders' Equity | -$1.30B | -$3.08B | $177.96B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MCK.